Short Adherence Intervention for Viral Re-suppression
Launched by SWISS TROPICAL & PUBLIC HEALTH INSTITUTE · Aug 7, 2017
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Due to a lack of routine viral load (VL) monitoring in Lesotho until now, most health care workers in the districts lack the necessary information on how to manage patients with elevated viral loads. The CART-1 study found re-suppression rates of only 30% with only 70% returning for a second VL. From these estimates, it is clear that the current practice for managing these patients must be improved. A simple intervention has been designed that could be feasibly adapted at all health centres in Lesotho.
To ensure that the effect of this intervention is measured and to avoid a long delay in ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients receiving VL monitoring at one of the 2 hospitals and 10 health centres in Butha-Buthe district
- • Patients on first-line ART
- • Patients with a VL≥ 1000 copies/mL after a minimum of 6 months on first-line ART
- Exclusion Criteria:
- • Patients receiving VL monitoring at a non-participating center in Butha-Buthe
About Swiss Tropical & Public Health Institute
The Swiss Tropical and Public Health Institute (Swiss TPH) is a leading research organization dedicated to enhancing global health through innovative scientific research, education, and capacity building. Based in Basel, Switzerland, Swiss TPH focuses on infectious diseases, global health systems, and public health interventions, aiming to translate scientific findings into practical solutions for communities in need. With a multidisciplinary team of experts, the institute collaborates with international partners to conduct clinical trials and implement evidence-based strategies that address pressing health challenges, particularly in low- and middle-income countries. Through its commitment to excellence and sustainability, Swiss TPH plays a pivotal role in advancing health equity and improving health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Butha Buthe, , Lesotho
Patients applied
Trial Officials
Tracy R Glass, PhD
Principal Investigator
Swiss TPH
Niklaus Labhardt, MD
Study Chair
Swiss TPH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials